scholarly journals Development of Recombinant Vaccines in Lactobacilli for Elimination of Salmonella

2011 ◽  
Vol 30 (4) ◽  
pp. 93-98 ◽  
Author(s):  
Akinobu Kajikawa ◽  
Shizunobu Igimi
Keyword(s):  
Recombinant Vaccines

Prediction of the Omp16 Epitopes for the Development of an Epitope-based Vaccine Against Brucellosis

2019 ◽  
Vol 19 (1) ◽  
pp. 36-45 ◽  
Author(s):  
Marzieh Rezaei ◽  
Mohammad Rabbani-khorasgani ◽  
Sayyed Hamid Zarkesh-Esfahani ◽  
Rahman Emamzadeh ◽  
Hamid Abtahi
Keyword(s):  
Immune Responses ◽  
B Cell ◽  
Dairy Products ◽  
Bioinformatics Analysis ◽  
Epitope Prediction ◽  
Animal Husbandry ◽  
Zoonotic Diseases ◽  
Recombinant Vaccines ◽  
Protective Capacity ◽  
Tertiary Structures

Background:Brucellosis is an infectious disease caused by Brucella bacteria that cause disease in animals and humans. Brucellosis is one of the most common zoonotic diseases transmitted from animals-to-human through direct contact with infected animals and also consumption of unpasteurized dairy products. Due to the wide incidence of brucellosis in Iran and economical costs in industrial animal husbandry, Vaccination is the best way to prevent this disease. All of the available commercial vaccines against brucellosis are derived from live attenuated strains of Brucella but because of the disadvantage of live attenuated vaccines, protective subunit vaccine against Brucella may be a good candidate for the production of new recombinant vaccines based on Brucella Outer Membrane Protein (OMP) antigens. In the present study, comprehensive bioinformatics analysis has been conducted on prediction software to predict T and B cell epitopes, the secondary and tertiary structures and antigenicity of Omp16 antigen and the validation of used software confirmed by experimental results.Conclusion:The final epitope prediction results have proposed that the three epitopes were predicted for the Omp16 protein with antigenicity ability. We hypothesized that these epitopes likely have the protective capacity to stimulate both the B-cell and T-cell mediated immune responses and so may be effective as an immunogenic candidate for the development of an epitope-based vaccine against brucellosis.

scholarly journals An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Anupama M. Gudadappanavar ◽  
Jyoti Benni
Keyword(s):  
Antiviral Drug ◽  
Drug Repurposing ◽  
Respiratory Illness ◽  
World Health ◽  
Recombinant Vaccines ◽  
Subunit Vaccines ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Full Length Genome

AbstractA novel coronavirus infection coronavirus disease 2019 (COVID-19) emerged from Wuhan, Hubei Province of China, in December 2019 caused by SARS-CoV-2 is believed to be originated from bats in the local wet markets. Later, animal to human and human-to-human transmission of the virus began and resulting in widespread respiratory illness worldwide to around more than 180 countries. The World Health Organization declared this disease as a pandemic in March 2020. There is no clinically approved antiviral drug or vaccine available to be used against COVID-19. Nevertheless, few broad-spectrum antiviral drugs have been studied against COVID-19 in clinical trials with clinical recovery. In the current review, we summarize the morphology and pathogenesis of COVID-19 infection. A strong rational groundwork was made keeping the focus on current development of therapeutic agents and vaccines for SARS-CoV-2. Among the proposed therapeutic regimen, hydroxychloroquine, chloroquine, remdisevir, azithromycin, toclizumab and cromostat mesylate have shown promising results, and limited benefit was seen with lopinavir–ritonavir treatment in hospitalized adult patients with severe COVID-19. Early development of SARS-CoV-2 vaccine started based on the full-length genome analysis of severe acute respiratory syndrome coronavirus. Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline. This article concludes and highlights ongoing advances in drug repurposing, therapeutics and vaccines to counter COVID-19, which collectively could enable efforts to halt the pandemic virus infection.

Uses of vaccinia virus as a vector for the production of live recombinant vaccines

BioEssays ◽  
1984 ◽  
Vol 1 (3) ◽  
pp. 120-124 ◽  
Author(s):  
Geoffrey L. Smith ◽  
Bernard Moss
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccines

scholarly journals Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B

2004 ◽  
Vol 99 (8) ◽  
pp. 865-871 ◽  
Author(s):  
Reinaldo Menezes Martins ◽  
Gilberta Bensabath ◽  
Luiz Claudio Arraes ◽  
Maria de Lourdes Aguiar Oliveira ◽  
Juliana Custódio Miguel ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Multicenter Study ◽  
Recombinant Vaccines

The use of vaccinia virus for the construction of recombinant vaccines

BioEssays ◽  
1986 ◽  
Vol 5 (6) ◽  
pp. 248-252 ◽  
Author(s):  
Antonia Piccini ◽  
Enzo Paoletti
Keyword(s):  
Vaccinia Virus ◽  
Recombinant Vaccines
Sign in / Sign up

Export Citation Format

Share Document